论文部分内容阅读
急诊溶栓是早期治疗急性心肌梗死(AMI)、肺栓塞、急性缺血性脑卒中(ACIS)的有效措施。过去20多年里,急诊溶栓的开展使急性血栓性疾病的病死率大幅度下降。随着溶栓药物的发展,急诊溶栓治疗的效果进一步提高。临床常用的溶栓药物有:尿激酶(UK)、链激酶(SK)及重组组织型纤溶激活剂(rt-PA)。天然提取的溶栓剂如吸血蝙蝠唾液纤溶酶原激活剂、葡激酶(SAK)显示出良好的应用前景。植物中发现的抗纤溶酶原激活物的抑制剂化合物 PUW-1,可能避免出血副作用,它是惟一可口服的溶栓药。一、AMI 的溶栓治疗过程与评估1.适应证:(1)持续胸痛≥30 min,服硝酸甘油后症状不
Emergency thrombolysis is an effective measure for the early treatment of acute myocardial infarction (AMI), pulmonary embolism, acute ischemic stroke (ACIS). Emergency thrombolysis has dramatically reduced the mortality rate of acute thrombotic diseases over the past two decades. With the development of thrombolytic drugs, the effect of emergency thrombolytic therapy is further improved. Thrombolytic drugs commonly used clinically: urokinase (UK), streptokinase (SK) and recombinant tissue fibrinolysis activator (rt-PA). Natural extracts of thrombolytic agents such as vomiting bat salivary plasminogen activator, staphylokinase (SAK) showed a good prospect. PUW-1, an inhibitor of plasminogen activator found in plants, may avoid bleeding side effects and is the only orally available thrombolytic. First, AMI thrombolytic treatment process and evaluation 1. Indications: (1) sustained chest pain ≥ 30 min, after taking nitroglycerin, the symptoms are not